Abstracts tagged "Co-morbidities and rheumatoid arthritis (RA)"

Abstract Number: 1550 • 2016 ACR/ARHP Annual Meeting
Comorbidities of Rheumatoid Arthritis: Results from the Korean National Health and Nutrition Examination Survey
Hyemin Jeong¹, Young Hee Eun², Eun-Jung Park³, Hyungjin Kim⁴, Ji Young Chae⁵, Jaejoon Lee¹, Hoon-Suk Cha² and Eun-Mi Koh⁴, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Department of Medicine, Division of Rheumatology, Department of Medicine, Jeju National University Hospital, Jeju University School of Medicine, Jeju, South Korea, ⁴Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁵Departement of Internal Medicine, Bundang Jesaeng General Hospital, Seongnam, Korea, The Republic of
Background/Purpose: To evaluate the prevalence of comorbidities in patients with rheumatoid arthritis (RA) compared with non-RA population. Methods: The 2010-2012 Korea National Health…
Abstract Number: 1406 • 2014 ACR/ARHP Annual Meeting
Comorbidity in Rheumatoid Arthritis. It Is Feasible to Record Concomitant Medical Conditions and Multi-Morbidity in Observational Research Studies. Can This be Extended to Routine Clinical Settings?
Elena Nikiphorou¹, Sam Norton² and Adam Young³, ¹School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, ²Institute of Psychiatry, King's College London, London, United Kingdom, ³Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom
Background/Purpose Comorbidity in RA can delay diagnosis and influence treatment decisions. It is known to affect RA outcomes, and can confound data analysis. Most RA…
Abstract Number: 462 • 2013 ACR/ARHP Annual Meeting
Reduced Response To Biologic Treatments in Rheumatoid Arthritis Patients Affected By Arterial Hypertension
Marco Antivalle¹, Michel Chevallard², Michele Battellino², Alberto Batticciotto³, Maria Chiara Ditto², Alessandra Mutti¹, Federica Rigamonti⁴, Valentina Varisco², Sara Bongiovanni², Fabiola Atzeni⁵ and Piercarlo Sarzi-Puttini⁶, ¹Rheumatology, L. Sacco University Hospital, Milano, Italy, ²Rheumatology, Rheumatology Unit, L. Sacco University Hospital, Milano, Italy, ³Rheumatology, Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ⁴Rheumatology Unit, L. Sacco University Hospital, Milano, Italy, ⁵Rheumatology, Rheumatology Unit, L. Sacco University Hospital, MiIano, Italy, ⁶Rheumatology Unit, L. Sacco University Hospital, Milan, Italy
Background/Purpose: Several reports show that the presence of comorbidities negatively influences both functional status (1) and quality of life (2) in rheumatoid arthritis (RA). No…
Abstract Number: 417 • 2013 ACR/ARHP Annual Meeting
Consensus Statement On The Diagnosis and Management Of Comorbidity In Rheumatoid Arthritis
Cristina Lajas¹, José Luis Andreu², Alejandro Balsa³, Manuel Crespo⁴, Carlos M. Gonzalez⁵, Oscar Illera⁶, Juan A. Jover¹, Isabel Mateo⁷, Javier Orte⁸, Javier Rivera⁹, Jose M Rodriguez-Heredia¹⁰, Fredeswinda I. Romero¹¹, Juan A Martínez-López¹², Ana M. Ortiz¹³, Esther Toledano¹, Virginia Villaverde¹⁴, Estibaliz Loza¹⁵, Loreto Carmona^16,17 and Santos Castañeda¹⁸, ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Rheumatology, Puerta de Hierro Universitary Hospital, Madrid, Spain, ³Rheumatology unit, La Paz University Hospital, Rheumatology, Madrid, Spain, ⁴Hospital universitario Severo Ochoa, Madrid, Spain, ⁵Rheumatology, Gregorio Marañon Hospital, Madrid, Spain, ⁶Rheumatology, Hospital Infanta Sofía, Madrid, Spain, ⁷Servicio De Reumatología, Hospital 12 De Octubre,, Madrid, Spain, ⁸Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁹Instituto Provincial de Rehabilitación, Madrid, Spain, ¹⁰Hospital Universitario de Getafe, Getafe, Spain, ¹¹Section for Autoimmune Diseases, Rheumatology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ¹²Rheumatology, Section for Autoimmune Diseases, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ¹³Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁴Rheumatology, Hospital Universitario de Móstoles, Mostoles, Spain, ¹⁵Institu, Madrid, Spain, ¹⁶Institute for Musculoskeletal Health, Madrid, Spain, ¹⁷Health Sciences School, Universidad Camilo José Cela, Villanueva de la Cañada, Spain, ¹⁸Rheumatology, Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain
Background/Purpose: comorbidity in rheumatoid arthritis (RA) is very important because it might delay diagnosis and influence treatment decisions. It is usually related to complications, alters…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].